Kyle LaPenna, MD, PhD (@kyle_lapenna) header
Kyle LaPenna, MD, PhD (@kyle_lapenna) profile picture

PGY-3 Internal Medicine Resident @weillcornell | Aspiring #cardiologist 🫀 and current cardiology fellowship applicant | via @LSUHealthNO @penn_state

New York, NY
Joined January 2022
Photo by Kyle LaPenna, MD, PhD (@kyle_lapenna)Photo by Kyle LaPenna, MD, PhD (@kyle_lapenna)Photo by Kyle LaPenna, MD, PhD (@kyle_lapenna)Photo by Kyle LaPenna, MD, PhD (@kyle_lapenna)Photo by Kyle LaPenna, MD, PhD (@kyle_lapenna)Photo by Kyle LaPenna, MD, PhD (@kyle_lapenna)
Excited that I’ve now submitted my fellowship application for Cardiovascular Disease Fellowship Match, AAMC ID: 14338569. Thrilled for what the future holds! – at Manhattan, NY
2
365
Kyle LaPenna, MD, PhD retweeted
44% of registered HF clinics now run a cardiac amyloidosis program — the most common HF subspecialty in the database, and spreading beyond academic centers. 🔗 hfsa.org/hfsa-heart-failure-…... #CardiacAmyloidosis #CardioTwitter
1
4
283
Kyle LaPenna, MD, PhD retweeted
Among older adults, worsening #Frailty, lower intrinsic capacity, and poorer physical health-related quality of life preceded #CardiovascularDisease events and accelerated in the 5 years before onset. ja.ma/48Ix7B9
1
6
1
16
2,464
Kyle LaPenna, MD, PhD retweeted
Excited to present our CADENCE echo results at #AHA26 with sim pub in @CircAHA! ahajournals.org/doi/abs/10.1… Sotatercept improved right & left heart structure in CpcPH-HFpEF, with some of the largest LAVI reductions reported in HFpEF. Looking forward to Phase 3 #CHORUS!
3
19
77
2,982
Kyle LaPenna, MD, PhD retweeted
Thanks for sharing the results of our IRONMET-HFpEF trial #AHA26 Mike! The full manuscript is available now, open access, at #Circulation. doi.org/10.1161/CIRCULATIONA…
Dr. Gregory Lewis and Dr. C. Michael Gibson discuss the IRONMET-HFpEF trial: Single-dose ferric derisomaltose infusion improved the primary endpoint of peak oxygen uptake at 12 weeks in patients with HFpEF and iron deficiency, showing benefits of enhanced functional capacity. Watch video here: clinicaltrialresults.org/wp-…
1
14
1
50
1,951
Kyle LaPenna, MD, PhD retweeted
Editor’s Perspective: New CADENCE data showed favorable right heart and left atrial changes with sotatercept in combined post- and precapillary pulmonary hypertension with #HFpEF. What do they mean? In this week’s @CircAHA, Mukherjee (@MMukherjeeMD) and Bogaard (@BogaardHarm) weigh the reductions in RV and LA size against lower resting cardiac output, and outline what to measure next. Here’s why it matters: smaller chambers are encouraging, but whether that means better intrinsic cardiac function needs more testing. #AHA26 @AHAScience Commentary: ahajournals.org/doi/10.1161/… CADENCE echo analysis: ahajournals.org/doi/10.1161/…
2
10
17
970
Kyle LaPenna, MD, PhD retweeted
🧠💭Cognition and neurodegeneration 🧠 in ❤️CVD - What can cognitive change reveal about 🫀cardiovascular care? Speaker @ParagGoyalMD | Nov 6, 9:45 AM CT | N138, McCormick Place. @CVSNHeart @AHAScience #AHA2026
3
1
96
Kyle LaPenna, MD, PhD retweeted
Happening now #AHA2026, the session on Mechanisms of HFpEF is ongoing! Dr. Koleini is presenting now on metabolic dysregulation as a driver of disease. Come stop by room S102BC to see this and the following talks! @AHAScience @AHAMeetings #BCVS
4
4
7
379
Kyle LaPenna, MD, PhD retweeted
Happening now at #ScientificSessions26 is the mechanisms of HFpEF session. Come and learn about the latest scientific discoveries in S102BC
5
19
584
Kyle LaPenna, MD, PhD retweeted
Excited to share our @CircHF editorial on a REHAB-HF study answering: "Who benefits most from HF rehab?" @DrDamluji @robmentz found Pts. who were the most inflamed by hsCRP gained the most from rehab Thanks to @ambarish4786 @DrNancySweitzer for the opportunity to contribute!
3
10
1
37
2,508
Kyle LaPenna, MD, PhD retweeted
3 in 10 U.S. adults use AI chatbots for health information. Almost 1 in 5 say they cannot afford to see a provider. @FDA asked how it should judge these systems. My answer starts w/the comparator. Comments close today. My @JACCJournals Editor’s Page: jacc.org/doi/10.1016/j.jacc.…
3
15
1
44
5,708
Kyle LaPenna, MD, PhD retweeted
In HFpEF, the randomized clinical trial evidence supporting the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenoneis more robust than that supporting steroidal MRAs, such as eplerenone. Steve Greene and I examine the differences between steroidal and nonsteroidal MRAs, the contrasting findings from randomized clinical trials, and the 2026 Expert Consensus Decision Pathway (ECDP) guidance on optimizing treatment with SGLT2 inhibitors and finerenone in patients with HFpEF. The key takeaway? A shared mechanism of action does not necessarily translate into equivalent clinical outcomes. When making treatment decisions, it is the evidence for the individual agent, not simply the drug class, that matters. Watch our discussion to learn why not all MRAs are created equal. clinicaltrialresults.org/wp-… #HFpEF #Finerenone #HeartFailure #Cardiology #EvidenceBasedMedicine s/b Bayer
2
20
67
6,653
Kyle LaPenna, MD, PhD retweeted
Day 2 plenary session of #HFSA2026 featuring the formidable #Matt #Maurer presenting results from the #REVEAL study about use of Evuzamitide-based PET imaging for early detection of cardiac amyloidosis.
1
1
3
334
Kyle LaPenna, MD, PhD retweeted
Starting now! Kickoff Session: #HFpEF Mechanistic Insights and Therapeutic Innovation! Come hear the latest and greatest in HFpEF! @HFSA @JCardFail @LitwinSheldon @ambarish4786 @FudimMarat Milton Packer @poojaprasad91
3
12
1,025
Kyle LaPenna, MD, PhD retweeted
See #HFStats in action at #HFSA2026 starting tonight! 1️⃣ Attend the session at 5pm MT w/ @EiranGorodeski + @ParagGoyalMD 2️⃣ Learn about hfstats.org in the Atrium HFSA Discovery Hub 3️⃣ and vote for which 2026 stat surprised you most
5
19
933
Kyle LaPenna, MD, PhD retweeted
Dr. David Aguilar is a professor at UT Southwestern Medical Center in Dallas, Texas, specializing in cardiology, cardiovascular disease prevention and cardiometabolic diseases such as hypertension, diabetes and obesity. He is a fellow of the American Heart Association and the American College of Cardiology. He also serves on the editorial boards of several renowned medical journals, and previously led work in healthy aging and longevity at LSU Health New Orleans in New Orleans, Louisiana. Dr. Aguilar has delivered numerous national and international presentations and published more than 100 academic articles, reviews and book chapters related to his areas of expertise. Thank you, Dr. Aguilar, for helping us advance our mission to be a relentless force for a world of longer, healthier lives! This month, we’re honoring the strength of Hispanic and Latino communities across the U.S. and celebrating the changemakers transforming heart and brain health across communities. Together we can create healthier futures for all. #HispanicHeritageMonth #LegacySeries
3
5
1
30
7,022
Kyle LaPenna, MD, PhD retweeted
Among older adults in the US, use of prescription medications and dietary supplements remained common between 2015-2016 and 2021-2023, while polypharmacy involving both categories increased. More than 1 in 5 older adults in 2021-2023 were potentially at risk of a major drug-drug interaction, a finding relevant to medication safety, deprescribing, and adverse drug event prevention. ja.ma/3VPfmwL
4
35
82
13,146
Kyle LaPenna, MD, PhD retweeted
1) Sotatercept is amazing effective for PAH but effects on the RV have been inconsistent. @CircAHA we show that RV contractility truly decreases after sotatercept with no change in RV PA coupling -> the surrogates we’ve chased for years with vasodilators ahajournals.org/eprint/ZXDH2…
5
19
60
5,630
Our incredible 2nd year fellow and rising interventionalist Dr. Axman gave a brilliant and heroic clinical case presentation on SCAD and its management. We’re also thankful there was no traffic - this was not one to miss!!
1
5
565
Kyle LaPenna, MD, PhD retweeted
It's that time of the year again: @NobelPrize Season! Just as fun as #MarchMadness but far more consequential! Here is my pick for 2026 Nobel Prize in #Physiology & #Medicine: Svetlana Mojsev (Rockfeller U), @DanielJDrucker (U of Toronto), & Jens Juul Holst (U of Copenhagen) for their pioneering work on Glucagon-Like Peptide-1 (GLP-1) biology. Who hasn't heard of GLP-1 receptor agonists Wegovy and Ozempic? They treat type 2 diabetes, obesity, obstructive apnea & addiction. Also, it's easy to forget that they also prevents heart attacks and strokes! My medical school's physiology class probably covered it, but young me probably wondered why we should care about GLP-1 when we have glucagon, I believe Joel Habener (MGH) should be included, but he died last year. #ScienceSavesLives
2
5
341
Kyle LaPenna, MD, PhD retweeted
In advanced HF, the survival equation changes on counting waitlist time in older patients; decisions must consider entire treatment journey, not just post-therapy outcomes. Now in @JACCJournals #JACCHF jacc.org/doi/10.1016/j.jchf.… @NirUrielMD @yuzefpolskaya @ilanrichter et al
6
19
1,301